erlotinib hydrochloride has been researched along with 7,8-dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (7,8-dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide) | Trials (7,8-dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide) | Recent Studies (post-2010) (7,8-dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 1,201 | 6 | 149 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumeister, P; Harréus, U; Heinrich, K; Märte, M; Reiter, M; Schwenk-Zieger, S | 1 |
1 other study(ies) available for erlotinib hydrochloride and 7,8-dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide
| Article | Year |
|---|---|
The impact of EGFR stimulation and inhibition on BPDE induced DNA fragmentation in oral/oropharyngeal mucosa in vitro.
Topics: 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Case-Control Studies; Cetuximab; Cisplatin; DNA Damage; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Oropharyngeal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tumor Necrosis Factor-alpha; Up-Regulation; Young Adult | 2011 |